Tenvir EM Tablet

Tenvir EM Tablet contains two active ingredients: Emtricitabine 200 mg and Tenofovir Disoproxil Fumarate 300 mg. These two compounds are combined into a single tablet. Cipla, India produces this product as a fixed-dose combination in the antiretroviral treatment category.

Get HIV Treatment carries Tenvir EM Tablet for resellers and bulk buyers looking to stock a high-demand antiretroviral line.

What This Product Treats

Tenvir EM Tablet is used for Human Immunodeficiency Virus infection. The combination covers both treatment of established infection and pre-exposure prevention in high-risk populations. Demand for this product is stable across multiple markets. Resellers supplying clinics, pharmacies, and community health programs stock this product consistently because of its dual-use profile and well-established demand.

How It Works

Both active compounds in this product belong to the nucleotide reverse transcriptase inhibitor drug class. They work by entering the viral replication cycle and blocking the reverse transcriptase enzyme. Reverse transcriptase is the enzyme the virus uses to copy its genetic material into DNA inside the human cell. Without that step, the virus cannot produce new copies of itself. Emtricitabine and Tenofovir Disoproxil Fumarate each target the same enzyme through slightly different binding activity. Together they create a more complete blocking effect. The virus stops multiplying.

Available Strengths and Pack Sizes

Buyers ordering Tenvir EM Tablet in bulk should confirm available pack configurations before placing a wholesale order. The standard strength is:

– Emtricitabine 200 mg plus Tenofovir Disoproxil Fumarate 300 mg — fixed-dose combination tablet

Pack sizes available for reseller ordering should be confirmed directly with the supplier at Get HIV Treatment, as bulk configurations may vary by order volume and market destination. This is the only strength in the Tenvir EM Tablet line. No higher or lower dose variants are listed in this product category.

Side Effect

The side effect profile of Tenvir EM Tablet is consistent with the nucleotide reverse transcriptase inhibitor drug class. Buyers stocking this product for distribution should be aware of the following profile characteristics:

• Nausea and vomiting
• Headache
• Dizziness
• Diarrhea
• Fatigue
• Skin discoloration or rash
• Kidney function changes with long-term use
• Changes in bone density markers in laboratory testing

These are known product-level characteristics tied to the active compounds. The profile is well-documented and widely referenced in published literature on this drug class. Buyers do not need to flag these as unexpected findings. The combination is listed on the World Health Organization essential medicines list, which reflects its accepted safety and efficacy record.

Shelf Life, Storage, and Packaging

Tenvir EM Tablet should be stored at room temperature, generally between 15 and 30 degrees Celsius. Exposure to high humidity or direct sunlight will degrade the tablet coating. Packaging is blister format, which provides individual tablet protection during storage and transport. This matters for resellers managing long shipping routes or warehouse stock. Buyers handling large Tenvir EM Tablet bulk orders should store stock in a cool, dry environment away from direct light. Shelf life should be confirmed on the batch documentation at the time of ordering.

Pricing and Availability

Get HIV Treatment offers Tenvir EM Tablet at competitive pricing for resellers and stockists. Pricing per strip and per unit varies based on order volume. Buyers placing a Tenvir EM Tablet bulk order will find that per-unit cost decreases at higher quantities, which makes this product a strong option for resellers managing tight margins. Confirm current pricing directly through the product listing. This product is available for online ordering where regulations in the destination market permit importation of antiretroviral medicines.

Why Buyers Choose This Product

Cipla India is a recognized name in the generic antiretroviral manufacturing space. The product meets the quality expectations that resellers and institutional buyers require for this treatment category. Market demand for Emtricitabine plus Tenofovir Disoproxil Fumarate combinations is ongoing and not seasonal. Buyers working as Tenvir EM Tablet suppliers to clinics, distributors, or community programs will find consistent reorder cycles. The World Health Organization listing gives procurement teams and resellers a clear quality benchmark when sourcing this combination for their supply chains.